Pyrazoloacridine
Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC50 of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment[1][2].
Product Specifications
CAS Number
[99009-20-8]
Product Name Alternative
NSC 366140; PD 115934
UNSPSC
12352005
Target
Apoptosis; Topoisomerase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pyrazoloacridine.html
Purity
98.05
Solubility
DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=[N+](C1=CC=C2C3=C1NC4=CC=C(OC)C=C4C3=NN2CCCN(C)C)[O-]
Molecular Formula
C19H21N5O3
Molecular Weight
367.40
References & Citations
[1]J S Sebolt, et al. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res. 1987 Aug 15;47 (16) :4299-304.|[2]A A Adjei, et al. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4 (3) :683-91.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
050469-01 10 µg
POTE Ankyrin Domain Family, Member J (POTEJ), Recombinant, Human, His-Tag
Ask
View Details 
050469-02 50 µg
POTE Ankyrin Domain Family, Member J (POTEJ), Recombinant, Human, His-Tag
Ask
View Details